Cancer statistics, 2025
2025/01/01 by Rebecca L. Siegel, Tyler B. Kratzer, Angela N. Giaquinto +2 · 86 citations
Medicine · #Global Cancer Incidence and Screening #Pancreatic and Hepatic Oncology Research #Colorectal Cancer Screening and Detection
paper · pdf · doi:10.3322/caac.21871
Abstract
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2021) and mortality data collected by the National Center for Health Statistics (through 2022). In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2022, averting nearly 4.5 million deaths since 1991 because of smoking reductions, earlier detection for some cancers, and improved treatment. Yet alarming disparities persist; Native American people bear the highest cancer mortality, including rates that are two to three times those in White people for kidney, liver, stomach, and cervical cancers. Similarly, Black people have two-fold higher mortality than White people for prostate, stomach, and uterine corpus cancers. Overall cancer incidence has generally declined in men but has risen in women, narrowing the male-to-female rate ratio (RR) from a peak of 1.6 (95% confidence interval, 1.57-1.61) in 1992 to 1.1 (95% confidence interval, 1.12-1.12) in 2021. However, rates in women aged 50-64 years have already surpassed those in men (832.5 vs. 830.6 per 100,000), and younger women (younger than 50 years) have an 82% higher incidence rate than their male counterparts (141.1 vs. 77.4 per 100,000), up from 51% in 2002. Notably, lung cancer incidence in women surpassed that in men among people younger than 65 years in 2021 (15.7 vs. 15.4 per 100,000; RR, 0.98, p = 0.03). In summary, cancer mortality continues to decline, but future gains are threatened by rampant racial inequalities and a growing burden of disease in middle-aged and young adults, especially women. Continued progress will require investment in cancer prevention and access to equitable treatment, especially for Native American and Black individuals.
Cited by
- Prostate cancer statistics, 2025
- Cancer treatment and survivorship statistics, 2025
- Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future
- From testosterone to 11-oxygenated androgens: Integrating endocrine biology, nutrition, and systemic health across the lifespan
- HDAC6 is a biomarker of leukaemic dissemination and relapse in B-ALL
- Ultraprocessed food intake and postmenopausal breast cancer risk in the NIH-AARP Diet and Health Study
- Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
- Detection of Cancers Three Years prior to Diagnosis Using Plasma Cell-Free DNA
- LASER: A Phase 2 Trial of <sup>177</sup> Lu-PSMA-617 as Systemic Therapy for RCC
- Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-guided Subtyping and Lesion-Wise Model Ensemble
- KLO-Net: A Dynamic K-NN Attention U-Net with CSP Encoder for Efficient Prostate Gland Segmentation from MRI
- KRAS G12D protein screening for pancreatic cancer clinical trials using an AlGaN/GaN high electron mobility transistor biosensor
- DermETAS-SNA LLM: A Dermatology Focused Evolutionary Transformer Architecture Search with StackNet Augmented LLM Assistant
- Advancing cancer research via comparative oncology
- Toward Scalable Early Cancer Detection: Evaluating EHR-Based Predictive Models Against Traditional Screening Criteria
- Cancer-Net PCa-MultiSeg: Multimodal Enhancement of Prostate Cancer Lesion Segmentation Using Synthetic Correlated Diffusion Imaging
- Validation of Fully-Automated Deep Learning-Based Fibroglandular Tissue Segmentation for Efficient and Reliable Quantitation of Background Parenchymal Enhancement in Breast MRI
- A Wireless Volumetric Metamaterial Resonator for Breast MRI
- Exploring the biology of metastatic hormone-sensitive prostate cancer: on the road to precision medicine
- Early pembrolizumab plasma levels as a prognostic biomarker in real-world NSCLC patients
- MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
- The changing landscape of urothelial carcinoma: on the edge of a paradigm shift
- Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis
- Land use, zoning, and breast cancer incidence in California: an ecological study
- Vaccines for preventing infections in adults with solid tumours
- Morphology-Aware Prognostic model for Five-Year Survival Prediction in Colorectal Cancer from H&E Whole Slide Images
- An Integrated Raman Platform with Embedded AI for Intraoperative Real-Time Cancer Detection
- A Dual‐Acceptor Engineered Second Near‐Infrared Ionic Aggregation‐Induced Emission Luminogen for Mitochondria‐Disrupted Cancer Phototheranostics
- The role of human microbiota in breast cancer pathogenesis and treatment
- State-level progress in reducing cervical cancer incidence among US young women between the pre- and post-human papillomavirus vaccination eras
- Colorectal cancer molecular profiling: Opportunities for early detection
- SoC-DT: Standard-of-Care Aligned Digital Twins for Patient-Specific Tumor Dynamics
- Interventions to Improve Adherence to Clinical Guidelines for the Management and Follow-Up of Pulmonary Nodules
- Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts
- Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy
- Diminishing Returns Among Black Patients With Cancer: The Intersection of Race and Neighborhood Socioeconomic Status
- Federal and state policies regulating short‐term limited‐duration insurance plans and timely cancer treatment initiation
- Dynamic Immune Cell Composition, Phenotypes, and Signaling in an Engineered Metastatic Niche
- TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma.
- Identification and credentialing of patient-derived xenograft models of invasive lobular carcinoma
- Methylation-based signature to distinguish indolent and aggressive prostate cancer
- Cancer-associated fibroblasts regulate DNA repair in pancreatic cancer through NDRG1-mediated R-loop processing
- Transforming docetaxel delivery: lung-targeted polyphosphazene nanoparticles with enhanced safety profile
- Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022
- TMPRSS2:ERG–directed radiosensitization: exploiting DNA repair rewiring in gene fusion–positive prostate cancer
- Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women
- Cancers in the US are increasing in women and younger people, data show
- Therapeutic Cancer Vaccines: Mechanisms, Clinical Progress, and Future Directions
- Plasticity, signaling, and metabolic rewiring in melanoma persister cells
- Incorporating external risk information with the Cox model under population heterogeneity: applications to trans-ancestry polygenic hazard scores
- Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens
- Hormonal Contraceptive Formulations and Breast Cancer Risk in Adolescents and Premenopausal Women
- Insulinemic and inflammatory dietary patterns and colorectal cancer risk: a dietary data harmonization study of one million participants in the Consortium of Metabolomics Studies (COMETS)
- Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer
- CE-RS-SBCIT A Novel Channel Enhanced Hybrid CNN Transformer with Residual, Spatial, and Boundary-Aware Learning for Brain Tumor MRI Analysis
- CellEcoNet: Decoding the Cellular Language of Pathology with Deep Learning for Invasive Lung Adenocarcinoma Recurrence Prediction
- Optimizing Prognostic Biomarker Discovery in Pancreatic Cancer Through Hybrid Ensemble Feature Selection and Multi-Omics Data
- Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non–Small Cell Lung Cancer
- The impact of genomic ancestry on tumor genomics in head and neck squamous cell carcinoma
- Leisure-Time Physical Activity and Cancer Mortality Among Cancer Survivors
- Identification of PIWI-interacting RNAs based models for lung adenocarcinoma early detection: a multicenter cohort study
- Recent Advances and Evolving Strategies of Photothermal Immunotherapy in Pancreatic Cancer Treatment
- Cancer statistics for African American and Black people, 2025. [europepmc]
- Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2. [europepmc]
- Prognostic value of combined NP and LHb index with absolute monocyte count in colorectal cancer patients. [europepmc]
- Multicancer early detection testing: Guidance for primary care discussions with patients. [europepmc]
- Preoperative pan-immuno-inflammatory values and albumin-to-globulin ratio predict the prognosis of stage I-III colorectal cancer. [europepmc]
- Harnessing engineered extracellular vesicles for enhanced therapeutic efficacy: advancements in cancer immunotherapy. [europepmc]
- Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. [europepmc]
- Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. [europepmc]
- ST6GalNAc-I regulates tumor cell sialylation via NECTIN2/MUC5AC-mediated immunosuppression and angiogenesis in non-small cell lung cancer. [europepmc]
- Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. [europepmc]
- Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. [europepmc]
- Tumor-Associated Macrophages: Polarization, Immunoregulation, and Immunotherapy. [europepmc]
- Cancer treatment and survivorship statistics, 2025. [europepmc]
- Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside. [europepmc]
- Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management. [europepmc]
- Early-Onset Gastrointestinal Cancers: A Review. [europepmc]
- Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders. [europepmc]
- PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. [europepmc]
- Early-onset colorectal cancer as an emerging disease of metabolic dysregulation. [europepmc]
- KRAS: the Achilles' heel of pancreas cancer biology. [europepmc]
- Prostate cancer statistics, 2025. [europepmc]
- The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast Cancer. [europepmc]
- Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future. [europepmc]
- Engineered exosomes with Kras G12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates. [europepmc]
- Single-cell and spatial transcriptome profiling identifies the immunosuppressive spatial niche in KRAS -mutant colorectal cancer. [europepmc]
Related